← Human Trials & Peer-Reviewed Studies
Vitamin D Supplementation Modulates Platelet-Mediated Inflammation in Subjects With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
Plain-language guide to PMID 35720377 (2022): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 201 subjects.
Key Facts
- PMID
- 35720377
- Journal
- Frontiers in immunology
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Johny E et al. (8 authors)
- DOI
- 10.3389/fimmu.2022.869591
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.
Hence, the researchers aimed to investigate the effect of vitamin D supplementation on platelet-mediated inflammation in T2DM patients.
Why It Was Studied
Clinical Trial Registry of India: CTRI/2019/01/016921.
Who Took Part
The abstract describes 201 subjects taking part.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The subjects were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
Blinding on both sides kept the subjects and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.
The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.
Serum vitamin D metabolite levels, immunome profiling, platelet activation, and platelet-immune cell aggregate formation were measured at baseline and at the end of the study.
Similarly, the serum levels of inflammatory cytokines/chemokines were assessed by a multiplex assay.
What Was Measured
Topics PubMed links to this paper include Cholecalciferol, Diabetes Mellitus, Type 2, Dietary Supplements, Inflammation, Vitamin D and Vitamins.
The authors tagged it with the keywords oxidative stress, platelet and type 2 diabetes.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 201 subjects.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2022 (Frontiers in immunology), a journal based in Switzerland.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.